SCHEMBL9860466

SCHEMBL9860466

COC(=O)c1c(C(=O)OC)c(-c2ccc(OC)c(OC)c2)c2c(OC)c(O)c(OC)cc2c1O

nearest known ligand 0.68

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC10A2 Q12908 3/20 0.68
PDE3B Q13370 4/20 0.46
PDE3A Q14432 4/20 0.46
PDE1A P54750 2/20 0.46
PDE1B Q01064 2/20 0.46
PDE1C Q14123 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MAPK1 P28482 2/20 0.44
MAPT P10636 2/20 0.44
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
ERN1 O75460 2/20 0.44
BCL9 O00512 1/20 0.41
CTNNB1 P35222 1/20 0.41
ABCC1 P33527 2/20 0.41
ABCG2 Q9UNQ0 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29740792 0.94 SLC10A2 (0.76) SLC10A2PDE3BPDE3APDE1APDE1B
SCHEMBL8688163 0.94 SLC10A2 (0.76) SLC10A2PDE3BPDE3APDE1APDE1B
SCHEMBL9777718 0.93 SLC10A2 (0.74) SLC10A2PDE3BPDE3APDE1APDE1B
SCHEMBL9777712 0.93 SLC10A2 (0.74) SLC10A2PDE3BPDE3APDE1APDE1B
SCHEMBL8684472 0.90 SLC10A2 (0.73) SLC10A2PDE3BPDE3APDE1APDE1B
SCHEMBL8682646 0.89 SLC10A2 (0.72) SLC10A2PDE3BPDE3APDE1APDE1B
SCHEMBL9860682 0.87 SLC10A2 (0.73) SLC10A2PDE3BPDE3APDE1APDE1B
SCHEMBL9861079 0.87 SLC10A2 (0.73) SLC10A2PDE3BPDE3APDE1APDE1B
SCHEMBL8683640 0.87 SLC10A2 (0.69) SLC10A2PDE3BPDE3APDE1APDE1B
SCHEMBL9860680 0.86 SLC10A2 (0.56) SLC10A2PDE3BPDE3APDE1APDE1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5070103-A ANTILIPEMIC AGENTS, ARTERIOSCLEROSIS TANABE SEIYAKU CO., LTD. (JP) 1991-12-03 US disclosed